MedTrace Logo

Impact MRSA -PCR on Patient Management

NCT03096405 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2017-05-30

No results posted yet for this study

Summary

Staphylococcus aureus represents one of the most met germs, with Escherichia coli, during bacteremia. Microbiologist distinguish at aureus S. two profiles of resistance in beta-lactamines: S. aureus sensitive to the methicillin ( SASM) and the S. aureus resistant to the methicillin ( SARM).

With the implementation of the MALDI-TOF, it is now possible to identify the origin responsible of the bacteremia the day of the positivity of the hemoculture ( J0) and to set up a treatment with adapted antibiotic, which, in the case of a sepsis to aureus S., is the vancomycine. Ye it was demonstrated, that the use of the vancomycine on the SASM increased the average duration of stay and a more important rate of relapse.

The PCR SARM was organized in the GHPSJ in 2014. It allows from the day of the positivity of the hemoculture ( J0), to determine the phenotype of resistance of S. aureus.

Conditions

  • MRSA Bacteremia

Interventions

DIAGNOSTIC_TEST

Polymerase Chain Reaction of Methicillin Resistant Staphyloccus Aureus

Polymerase Chain Reaction of Methicillin Resistant Staphyloccus Aureus

Sponsors & Collaborators

  • Fondation Hôpital Saint-Joseph

    lead OTHER

Principal Investigators

  • MIZRAHI Assaf, MD · Groupe Hospitalier Paris St JOSEPH

  • LEMONNIER Alban, MD · Groupe Hospitalier Paris St JOSEPH

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-02-01
Primary Completion
2016-03-31
Completion
2017-02-28

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03096405 on ClinicalTrials.gov